文献速递肝病消化道肿瘤与早癌

SLFN11缺失诱导的CCL2信号与巨噬细胞M2极化破坏增强肝细胞癌抗PD-1疗效

Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
PubMed 文献 · Gastroenterology · 2023-02-28

该研究通过转录组分析、人源化原位肝细胞癌小鼠模型和共培养体系,探讨SLFN家族在肝细胞癌免疫应答中的作用。发现SLFN11在对免疫检查点抑制剂应答的肿瘤中显著上调,其缺失通过CCL2依赖方式促进巨噬细胞M2极化和PD-L1表达,拮抗CCR2可增强抗PD-1疗效。

要点

  • SLFN11在对免疫检查点抑制剂应答的肝细胞癌肿瘤中显著上调。
  • SLFN11缺失通过CCL2依赖方式促进免疫抑制性巨噬细胞浸润和M2样极化。
  • 药理学拮抗CCR2可增强抗PD-1在SLFN11敲低肿瘤人源化小鼠中的抗肿瘤效果。

核心结论

  • SLFN11是微环境免疫特性的关键调节因子,也是肝细胞癌免疫检查点抑制剂应答的有效预测生物标志物。
  • 阻断CCL2/CCR2信号使SLFN11低表达的肝细胞癌患者对免疫检查点抑制剂治疗敏感。

研究设计与样本

  • 对人肝细胞癌组织进行转录组分析,比较对免疫检查点抑制剂有应答与无应答的样本。
  • 构建人源化原位肝细胞癌小鼠模型和共培养体系,并使用飞行时间流式细胞术探索SLFN11在肝细胞癌免疫微环境中的功能与机制。

主要发现

  • SLFN11在对免疫检查点抑制剂应答的肿瘤中显著上调。
  • 肿瘤特异性SLFN11缺失增加免疫抑制性巨噬细胞浸润并加重肝细胞癌进展。
  • SLFN11敲低的肝细胞癌细胞以CCL2依赖方式促进巨噬细胞迁移和M2样极化,进而通过激活NF-κB通路上调自身PD-L1表达。
  • SLFN11通过与TRIM21竞争性结合RBM10的RRM2结构域,抑制TRIM21介导的RBM10降解,稳定RBM10并促进NUMB外显子9跳跃,从而抑制Notch通路和CCL2转录。
  • 药理学拮抗CCR2增强了抗PD-1在携带SLFN11敲低肿瘤的人源化小鼠中的抗肿瘤效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The therapeutic effect of immune checkpoint inhibitors (ICIs) is poor in hepatocellular carcinoma (HCC) and varies greatly among individuals. Schlafen (SLFN) family members have important functions in immunity and oncology, but their roles in cancer immunobiology remain unclear. We aimed to investigate the role of the SLFN family in immune responses against HCC. METHODS: Transcriptome analysis was performed in human HCC tissues with or without response to ICIs. A humanized orthotopic HCC mouse model and a co-culture system were constructed, and cytometry by time-of-flight technology was used to explore the function and mechanism of SLFN11 in the immune context of HCC. RESULTS: SLFN11 was significantly up-regulated in tumors that responded to ICIs. Tumor-specific SLFN11 deficiency increased the infiltration of immunosuppressive macrophages and aggravated HCC progression. HCC cells with SLFN11 knockdown promoted macrophage migration and M2-like polarization in a C-C motif chemokine ligand 2-dependent manner, which in turn elevated their own PD-L1 expression by activating the nuclear factor-κB pathway. Mechanistically, SLFN11 suppressed the Notch pathway and C-C motif chemokine ligand 2 transcription by binding competitively with tripartite motif containing 21 to the RNA recognition motif 2 domain of RBM10, thereby inhibiting tripartite motif containing 21-mediated RBM10 degradation to stabilize RBM10 and promote NUMB exon 9 skipping. Pharmacologic antagonism of C-C motif chemokine receptor 2 potentiated the antitumor effect of anti-PD-1 in humanized mice bearing SLFN11 knockdown tumors. ICIs were more effective in patients with HCC with high serum SLFN11 levels. CONCLUSIONS: SLFN11 serves as a critical regulator of microenvironmental immune properties and an effective predictive biomarker of ICIs response in HCC. Blockade of C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 signaling sensitized SLFN11low HCC patients to ICI treatment.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Zhou C, Weng J, Liu C, et al. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma. Gastroenterology. 2023. PMID: 36863689. doi:10.1053/j.gastro.2023.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。